Literature DB >> 28808727

[25 years of the Association of Middle-German Otorhinolaryngologists (MDHNO)].

H Gudziol1.   

Abstract

Mesh：

Year:  2017        PMID： 28808727     DOI： 10.1007/s00106-017-0402-4

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


× No keyword cloud information.
  35 in total

1.  Responsiveness to cetuximab without mutations in EGFR.

Authors:  Zenta Tsuchihashi; Shirin Khambata-Ford; Nasser Hanna; Pasi A Jänne
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

2.  Recent advances in head and neck cancer.

Authors:  Robert I Haddad; Dong M Shin
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

3.  Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase.

Authors:  Klaus Dittmann; Claus Mayer; Birgit Fehrenbacher; Martin Schaller; Uma Raju; Luka Milas; David J Chen; Rainer Kehlbach; H Peter Rodemann
Journal:  J Biol Chem       Date:  2005-07-05       Impact factor: 5.157

4.  Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.

Authors:  B Jeremic; Y Shibamoto; B Milicic; N Nikolic; A Dagovic; J Aleksandrovic; Z Vaskovic; L Tadic
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity.

Authors:  Frank Hoebers; Wilma Heemsbergen; Suzanne Moor; Marta Lopez; Martin Klop; Margot Tesselaar; Coen Rasch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-28       Impact factor: 7.038

Review 6.  Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?

Authors:  Stuart J Wong; Mitchell Machtay; Yi Li
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

7.  Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.

Authors:  Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

8.  Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.

Authors:  Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

9.  Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies.

Authors:  Luka Milas; Zhen Fan; Nicolaus H Andratschke; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

10.  Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients.

Authors:  R De Crevoisier; J Bourhis; C Domenge; P Wibault; S Koscielny; A Lusinchi; G Mamelle; F Janot; M Julieron; A M Leridant; P Marandas; J P Armand; G Schwaab; B Luboinski; F Eschwege
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.